Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhancer and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects.
1. A method to safely and effectively treat an anxiety disorder, in a subject in need comprising:
(a) administering a receptor switcher, wherein the receptor switcher is n-acetyl-cysteine, to the subject; and
(b) administering an endorphin enhancer, wherein the endorphin enhancer is guarana, an exogeneous opioid, wherein the exogenous opioid is tramadol, and a synergistic enhancer, wherein the synergistic enhancer is L-theanine, to the subject.
2. The method of claim 1 , wherein:
(a) the Anxiety Disorder is selected from the group consisting of Panic Disorders, Agoraphobia, Specific Phobias, Social Phobias, Obsessive-Compulsive Disorder, Post-Traumatic Stress Disorder, Acute Stress Disorder, Generalized Anxiety Disorder, Substance-Induced Anxiety, Anxiety Related to Medical Disorders, Anxiety Disorder Not Otherwise Specified (NOS), as well as signs and symptoms of anxiety, stress, agitation, and worry that are not classified as an Anxiety Disorder.
3. The method of claim 1 , wherein the subject has previously taken an endorphin enhancer, an exogenous opioid, a synergistic enhancer, or any combination thereof.
4. A method to enhance the therapeutic benefit and/or reduce the side effects of the combination of an endorphin enhancer, wherein the endorphin enhancer is guarana, an exogenous opioid, wherein the exogenous opioid is tramadol, and a synergistic enhancer, wherein the synergistic enhancer is L-theanine when used for the treatment of an anxiety disorder, in a subject comprising:
co-administering to a subject a receptor switcher, wherein the receptor switcher is N-acetyl-cysteine, combined with an endorphin enhancer, wherein the endorphin enhancer is guarana, and a synergistic enhancer, wherein the synergistic enhancer is L-theanine.
5. The method of claim 1 , wherein:
(a) the mode of administration is selected from the group consisting of oral, pulmonary, nasal, sublingual, parenteral, and transdermal;
(b) the pharmaceutical formulation is delivered in a pharmaceutically-acceptable carrier that is rapid release, immediate-release, slow-release, delayed-released, controlled release, a combination of immediate release and controlled release, a nano-encapsulation formulations, and an abuse and/or tamper-resistant delivery system; or
(c) any combination thereof.